InvestorsHub Logo
Followers 6
Posts 120
Boards Moderated 0
Alias Born 06/28/2020

Re: BioInvestor4 post# 90514

Friday, 07/03/2020 11:04:19 PM

Friday, July 03, 2020 11:04:19 PM

Post# of 232939
I'm taking it back to bbcbro's post a week ago as to Trump's forthcoming 'therapeutics' announcement; IMO of course:

ACTIV is planning five master protocol trials, the first of which will test three host-targeted immune modulators against TNFa, CTLA-4 and CCR2/CCR5. The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) consortium is led by NIH and managed by the Foundation for NIH. Its members include 18 biopharma companies, FDA, CDC and the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR). BARDA is part of ASPR (see “ACTIV Coming into Focus”).


“Next week administration officials plan to promote a new study they say shows promising results on therapeutics, the officials said. They wouldn't describe the study in any further detail because, they said, its disclosure would be "market-moving”

https://www.google.com/amp/s/www.nbcnews.com/news/amp/ncna1232884

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News